EOM Pharmaceuticals Holdings, Inc.

IMUC

US4525364026

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:43:28 2024-04-19 am EDT			5-day change	1st Jan Change
0.1979 ^USD	+12.16%		+39.27%	-14.70%

2023	EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	CI
2023	EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	CI

ImmunoCellular Therapeutics, Ltd.(AMEX:IMUC) dropped from S&P TMI Index

October 18, 2018 at 12:00 am EDT

Latest news about EOM Pharmaceuticals Holdings, Inc.

EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	23-09-06	CI
EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	23-08-02	CI
EOM Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-20	CI
ImmunoCellular Therapeutics Ltd. has Changed its Name to EOM Pharmaceuticals Holdings, Inc	22-11-10	CI
EOM Pharmaceuticals Holdings, Inc. announced that it has received $0.75 million in funding	22-09-11	CI
EOM Pharmaceuticals Holdings, Inc. announced a financing transaction	22-08-25	CI
EOM Pharmaceuticals Holdings, Inc. has filed an IPO in the amount of $25 million.	22-06-24	CI
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	22-06-23	CI
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	22-02-09	CI
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.	21-12-01	CI
ImmunoCellular Therapeutics, Ltd.(AMEX:IMUC) dropped from S&P TMI Index	18-10-18	CI
ImmunoCellular Therapeutics, Ltd. Announces Executive Changes, Effective October 15, 2018	18-10-15	CI
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-16	CI
ImmunoCellular Therapeutics Is Considering Strategic Alternatives	18-08-13	CI
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-14	CI
ImmunoCellular Therapeutics, Ltd. Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program	18-04-12	CI
Transcript : ImmunoCellular Therapeutics, Ltd., Q4 2017 Earnings Call, Mar 13, 2018	18-03-13
ImmunoCellular Therapeutics, Ltd. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	18-03-13	CI
ImmunoCellular Considers Strategic Alternatives	18-02-22	CI
ImmunoCellular Therapeutics, Ltd. Achieves Stem-to-T-Cell Research Immuno-Oncology Program	17-12-13	CI
Transcript : ImmunoCellular Therapeutics, Ltd., Q3 2017 Earnings Call, Nov 21, 2017	17-11-21
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-21	CI
Certain Common Stock of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.	17-10-15	CI
Certain Options of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.	17-10-15	CI
Certain Restricted Stock Units of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.	17-10-15	CI

Chart EOM Pharmaceuticals Holdings, Inc.

Duration

Period

Chart EOM Pharmaceuticals Holdings, Inc.

More charts

EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their portfolio: EOM613 and EOM147. EOM613 is an investigational immunomodulator. EOM613 is a peptide-nucleic acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. EOM613 helps to suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells resulting in either further activation or suppression. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM147 affects multiple angiogenic growth factors such as VEGF, PdGF, and bFGF.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EOM PHARMACEUTICALS HOLDINGS, INC.	-14.70%	22.42M
IQVIA HOLDINGS INC.	-1.42%	41.52B
LONZA GROUP AG	+42.15%	39.9B
MODERNA, INC.	+1.97%	38.83B
CELLTRION, INC.	-14.19%	26.05B
ICON PUBLIC LIMITED COMPANY	+1.82%	23.78B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.26B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.65B
MEDPACE HOLDINGS, INC.	+21.36%	11.53B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.2B

Other Biotechnology & Medical Research

EOM Pharmaceuticals Holdings, Inc.

Equities

IMUC

US4525364026

Biotechnology & Medical Research

ImmunoCellular Therapeutics, Ltd.(AMEX:IMUC) dropped from S&P TMI Index

Latest news about EOM Pharmaceuticals Holdings, Inc.

Chart EOM Pharmaceuticals Holdings, Inc.

Company Profile

Sector Other Biotechnology & Medical Research